MedPath

A study of the clinical effects of 6-MSITC on chronic fatigue syndrome

Not Applicable
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome
Registration Number
JPRN-jRCTs031190205
Lead Sponsor
Oka Takakazu
Brief Summary

This study suggests that 6-MSITC-containing supplements (9.6 mg of 6-MSITC per day) are a safe and effective ingredient for especially improving PS levels and cognitive function in patients with ME/CFS. It was also suggested to improve the frequency of headaches and myalgia and to improve vitality and overall sense of wellness of patients with this illness. Therefore, 6-MSITC-containing supplements may be a useful treatment option for ME/CFS patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
15
Inclusion Criteria

1. Those who can be diagnosed as ME / CFS, according to the CDC diagnostic criteria (Fukuda1994) and the Ministry of Health, Labor and Welfare research group clinical diagnostic criteria (2017)
2. Those who are 20 to 69 years old (regardless of gender)
3. The performance status (severity of fatigue) is 3 and more, according to the ME / CFS clinical diagnostic criteria (2017), Table 3.
4. Those who can fill in self-rating questionnaires by themselves
5. Those who can come to the hospital at least once a month
6.Those whose consent judgment ability is judged to be sufficient

Exclusion Criteria

1. Those whose fatigue is due to known physical diseases (liver, kidney, heart, respiratory, endocrine, autoimmune, or malignant diseases, anemia, electrolyte abnormalities, etc.)
2. Women who are pregnant or breastfeeding, who may become pregnant or who wish to become pregnant during this study
3. Those who have taken or are currently taking supplements containing 6-MSITC
4. Those who are judged to be inappropriate by the principal investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Chalder Fatigue Scale Score
Secondary Outcome Measures
NameTimeMethod
1. Subjective symptoms<br>2. Quality of life and dysfunction indices (SF-36, ME/CFS PS)<br>3. Psychological indices (POMS2, HADS)<br>4. Physiological function indices (axillary temperature, non-invasive autonomic nervous function test, standing test, mechanical pain threshold)<br>5. Blood biomarkers<br>6. Sleep indices (Pittsburgh Sleep Quality Index, Sleep EEG)<br>7. Cognitive function indices (TMT-A)<br><br>Safety evaluation items<br>1. Blood test<br>2. Diseases
© Copyright 2025. All Rights Reserved by MedPath